At what value per share were the RSUs to Adrian Miranda reported in the NRXS Form 4?

The RSU grant to Adrian Miranda is reported at $6.28 per share . This figure reflects the value used for reporting purposes in the Form 4 and is tied to 133,341 restricted stock units representing common shares.

Neuraxis (NRXS) awards CMO 133K RSUs vesting over 3 years

Q: What equity award did Neuraxis (NRXS) grant to Adrian Miranda in this Form 4?

Neuraxis granted 133,341 restricted stock units (RSUs) to executive Adrian Miranda. Each RSU corresponds to one share of common stock and was issued as compensation under the company’s 2022 Omnibus Securities and Incentive Plan, as amended.

Q: How do the 133,341 RSUs granted by NRXS to Adrian Miranda vest?

The 133,341 RSUs vest in three equal annual installments over a three-year period. This means one-third of the units becomes vested each year, subject to the plan’s terms and any continued-service requirements.

Q: Under which plan were the NRXS RSUs to Adrian Miranda granted?

The award was granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended . The plan governs equity-based compensation, including these RSUs that vest in three equal annual installments over three years.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Miranda Adrian reported acquisition or exercise transactions in this Form 4 filing.

Neuraxis, Inc. reported an equity compensation grant to executive Adrian Miranda, its CMO and SVP Science & Tech. Miranda received 133,341 RSUs, each representing one share of common stock, as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs vest in three equal annual installments over three years, and Miranda now directly holds 133,341 RSUs tied to common shares.

Insights

Analyzing...

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miranda Adrian

Role CMO, SVP Science & Tech

Type	Security	Shares	Price	Value
Grant/Award	RSU ^F1	133,341	$6.28	$837K

Holdings After Transaction: RSU — 133,341 shares (Direct)

Footnotes (1)

F1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

Key Figures

RSUs granted: 133,341 shares Reported value per RSU: $6.28 per share Holdings after transaction: 133,341 shares +1 more

4 metrics

RSUs granted 133,341 shares Restricted stock units granted as compensation to Adrian Miranda

Reported value per RSU $6.28 per share Transaction price per share for RSU grant

Holdings after transaction 133,341 shares Total RSUs reported as directly held following the grant

Vesting schedule 3 equal annual installments over 3 years RSUs vest in three equal annual installments over a three-year period

Key Terms

restricted stock units (RSUs), 2022 Omnibus Securities and Incentive Plan, vest in three equal annual installments

3 terms

restricted stock units (RSUs) financial

"These shares of common stock are restricted stock units (RSUs) granted"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

2022 Omnibus Securities and Incentive Plan financial

"under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended"

vest in three equal annual installments financial

"The RSUs vest in three equal annual installments over a three-year period"

FAQ

What equity award did Neuraxis (NRXS) grant to Adrian Miranda in this Form 4?

Neuraxis granted 133,341 restricted stock units (RSUs) to executive Adrian Miranda. Each RSU corresponds to one share of common stock and was issued as compensation under the company’s 2022 Omnibus Securities and Incentive Plan, as amended.

How do the 133,341 RSUs granted by NRXS to Adrian Miranda vest?

The 133,341 RSUs vest in three equal annual installments over a three-year period. This means one-third of the units becomes vested each year, subject to the plan’s terms and any continued-service requirements.

What is Adrian Miranda’s reported NRXS holdings after this RSU grant?

Following the grant, Adrian Miranda is reported as directly holding 133,341 RSUs linked to Neuraxis common stock. These units represent potential future shares, subject to the specified three-year vesting schedule under the company’s incentive plan.

Under which plan were the NRXS RSUs to Adrian Miranda granted?

The award was granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The plan governs equity-based compensation, including these RSUs that vest in three equal annual installments over three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 06:36 PM Accepted by SEC EDGAR 08/17/2026 - 06:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miranda Adrian

(Last)

(First)

(Middle)

11611 N. MERIDIAN ST,

SUITE 330

(Street)

CARMEL

INDIANA

46032

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CMO, SVP Science & Tech

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
RSU	⁽¹⁾	08/13/2026		A		133,341		⁽¹⁾	⁽¹⁾	Common Stock	133,341	$6.28	133,341	D

Explanation of Responses:

1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

	/s/ Adrian Miranda	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR